Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 2/2016

01.02.2016 | Original Article

Correlation of Radiologic with Surgical Peritoneal Cancer Index Scores in Patients with Pseudomyxoma Peritonei and Peritoneal Carcinomatosis: How Well Can We Predict Resectability?

verfasst von: Kristina Flicek, Awais Ashfaq, C. Dan Johnson, Christine Menias, Sanjay Bagaria, Nabil Wasif

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Pseudomyxoma peritonei (PMP) and peritoneal carcinomatosis (PC) arises from primary or secondary peritoneal cancer and can be treated with complete surgical removal of disease. Suitability for surgery is based on a peritoneal cancer index (PCI), with a PCI ≥ 20 representing unresectable disease.

Aims

Compare preoperative imaging with surgical findings based on PCI.

Methods

All cases of patients with PMP and PC undergoing cytoreductive surgery ± hyperthermic intraperitoneal chemotherapy (HIPEC) between 2010 and 2014 were included. Two staff radiologists blinded to surgical PCI scores retrospectively reviewed imaging studies to calculate corresponding radiologic PCI scores for each patient. Correlation between radiologic PCI and surgical PCI, as obtained from operative reports, was assessed using Spearman’s rho correlation coefficients. Preoperative assessment of a PCI cutoff of 20 on imaging was compared with actual surgical PCI using sensitivity, specificity, and positive and negative predictive values.

Results

Forty-two patients had a mean surgical PCI ± SEM score of 15.1 ± 1.3 and mean radiologic PCI of 15.5 ± 1.5. The most common tumor histologies were appendiceal (60 %) and colon (33 %) adenocarcinoma and were of low tumor grade (67 %). Correlation between individual radiologists and surgical PCI was 0.59 and 0.62, respectively (all p < 0.001). When mean radiologic PCI was used, this correlation with surgical PCI improved to 0.64 and to 0.65 when good quality studies only were considered (all p < 0.001). Radiologic PCI score had a sensitivity of 76 %, a specificity of 69 %, positive predictive value of 85 %, and a negative predictive value of 56 % when compared with the surgical PCI. In patients with a radiologic PCI score ≥ 20, 6/13 (46 %) still achieved adequate cytoreduction.

Conclusions

Good quality cross-sectional imaging, combined with overreading and formal assessment of all components of the PCI score yields the best correlation with actual surgical findings. Although preoperative assessment of PCI ≥ 20 was reasonably accurate, using this cutoff to assess resectability is problematic as almost half of these patients were still able to undergo adequate cytoreduction. Better assessment of resectability is needed preop, either by refinement of the PCI criteria or routine staging laparoscopy.
Literatur
1.
Zurück zum Zitat Mann WJ, Jr., Wagner J, Chumas J, et al.: The management of pseudomyxoma peritonei. Cancer 66:1636–40, 1990CrossRefPubMed Mann WJ, Jr., Wagner J, Chumas J, et al.: The management of pseudomyxoma peritonei. Cancer 66:1636–40, 1990CrossRefPubMed
2.
Zurück zum Zitat Mukherjee A, Parvaiz A, Cecil TD, et al.: Pseudomyxoma peritonei usually originates from the appendix: a review of the evidence. Eur J Gynaecol Oncol 25:411–4, 2004PubMed Mukherjee A, Parvaiz A, Cecil TD, et al.: Pseudomyxoma peritonei usually originates from the appendix: a review of the evidence. Eur J Gynaecol Oncol 25:411–4, 2004PubMed
3.
Zurück zum Zitat Smith JW, Kemeny N, Caldwell C, et al.: Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan-Kettering Cancer Center experience. Cancer 70:396–401, 1992CrossRefPubMed Smith JW, Kemeny N, Caldwell C, et al.: Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan-Kettering Cancer Center experience. Cancer 70:396–401, 1992CrossRefPubMed
4.
Zurück zum Zitat Miner TJ, Shia J, Jaques DP, et al.: Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg 241:300–8, 2005PubMedCentralCrossRefPubMed Miner TJ, Shia J, Jaques DP, et al.: Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg 241:300–8, 2005PubMedCentralCrossRefPubMed
5.
Zurück zum Zitat Stephens AD, Alderman R, Chang D, et al.: Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 6:790–6, 1999CrossRefPubMed Stephens AD, Alderman R, Chang D, et al.: Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 6:790–6, 1999CrossRefPubMed
6.
Zurück zum Zitat Witkamp AJ, de Bree E, Kaag MM, et al.: Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer 37:979–84, 2001CrossRefPubMed Witkamp AJ, de Bree E, Kaag MM, et al.: Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer 37:979–84, 2001CrossRefPubMed
7.
Zurück zum Zitat Elias D, Quenet F, Goere D: Current status and future directions in the treatment of peritoneal dissemination from colorectal carcinoma. Surg Oncol Clin N Am 21:611–23, 2012CrossRefPubMed Elias D, Quenet F, Goere D: Current status and future directions in the treatment of peritoneal dissemination from colorectal carcinoma. Surg Oncol Clin N Am 21:611–23, 2012CrossRefPubMed
8.
Zurück zum Zitat Chua TC, Yan TD, Smigielski ME, et al.: Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol 16:1903–11, 2009CrossRefPubMed Chua TC, Yan TD, Smigielski ME, et al.: Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol 16:1903–11, 2009CrossRefPubMed
9.
Zurück zum Zitat Smeenk RM, Verwaal VJ, Antonini N, et al.: Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg 245:104–9, 2007PubMedCentralCrossRefPubMed Smeenk RM, Verwaal VJ, Antonini N, et al.: Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg 245:104–9, 2007PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Witkamp AJ, de Bree E, Kaag MM, et al.: Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg 88:458–63, 2001CrossRefPubMed Witkamp AJ, de Bree E, Kaag MM, et al.: Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg 88:458–63, 2001CrossRefPubMed
11.
Zurück zum Zitat Yan TD, Black D, Savady R, et al.: A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 14:484–92, 2007CrossRefPubMed Yan TD, Black D, Savady R, et al.: A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 14:484–92, 2007CrossRefPubMed
12.
Zurück zum Zitat Yan TD, Deraco M, Baratti D, et al.: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27:6237–42, 2009CrossRefPubMed Yan TD, Deraco M, Baratti D, et al.: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27:6237–42, 2009CrossRefPubMed
13.
Zurück zum Zitat Yan TD, Welch L, Black D, et al.: A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18:827–34, 2007CrossRefPubMed Yan TD, Welch L, Black D, et al.: A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18:827–34, 2007CrossRefPubMed
14.
Zurück zum Zitat Youssef H, Newman C, Chandrakumaran K, et al.: Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin. Dis Colon Rectum 54:293–9, 2011CrossRefPubMed Youssef H, Newman C, Chandrakumaran K, et al.: Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin. Dis Colon Rectum 54:293–9, 2011CrossRefPubMed
15.
Zurück zum Zitat Kuijpers AM, Mirck B, Aalbers AG, et al.: Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol 20:4224–30, 2013PubMedCentralCrossRefPubMed Kuijpers AM, Mirck B, Aalbers AG, et al.: Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol 20:4224–30, 2013PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Verwaal VJ, Bruin S, Boot H, et al.: 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15:2426–32, 2008CrossRefPubMed Verwaal VJ, Bruin S, Boot H, et al.: 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15:2426–32, 2008CrossRefPubMed
17.
Zurück zum Zitat Gilly FN, Cotte E, Brigand C, et al.: Quantitative prognostic indices in peritoneal carcinomatosis. Eur J Surg Oncol 32:597–601, 2006CrossRefPubMed Gilly FN, Cotte E, Brigand C, et al.: Quantitative prognostic indices in peritoneal carcinomatosis. Eur J Surg Oncol 32:597–601, 2006CrossRefPubMed
18.
Zurück zum Zitat Jacquet P, Sugarbaker PH: Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359–74, 1996CrossRefPubMed Jacquet P, Sugarbaker PH: Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359–74, 1996CrossRefPubMed
19.
Zurück zum Zitat Swellengrebel HA, Zoetmulder FA, Smeenk RM, et al.: Quantitative intra-operative assessment of peritoneal carcinomatosis—a comparison of three prognostic tools. Eur J Surg Oncol 35:1078–84, 2009CrossRefPubMed Swellengrebel HA, Zoetmulder FA, Smeenk RM, et al.: Quantitative intra-operative assessment of peritoneal carcinomatosis—a comparison of three prognostic tools. Eur J Surg Oncol 35:1078–84, 2009CrossRefPubMed
20.
Zurück zum Zitat Gilly FN, Carry PY, Sayag AC, et al.: Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology 41:124–9, 1994PubMed Gilly FN, Carry PY, Sayag AC, et al.: Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology 41:124–9, 1994PubMed
21.
Zurück zum Zitat Verwaal VJ, van Tinteren H, van Ruth S, et al.: Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 91:739–46, 2004CrossRefPubMed Verwaal VJ, van Tinteren H, van Ruth S, et al.: Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 91:739–46, 2004CrossRefPubMed
22.
Zurück zum Zitat da Silva RG, Sugarbaker PH: Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg 203:878–86, 2006CrossRefPubMed da Silva RG, Sugarbaker PH: Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg 203:878–86, 2006CrossRefPubMed
23.
Zurück zum Zitat Baratti D, Kusamura S, Deraco M: The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4–6, 2006): methodology of disease-specific consensus. J Surg Oncol 98:258–62, 2008CrossRefPubMed Baratti D, Kusamura S, Deraco M: The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4–6, 2006): methodology of disease-specific consensus. J Surg Oncol 98:258–62, 2008CrossRefPubMed
24.
Zurück zum Zitat Valle M, Federici O, Garofalo A: Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, and role of laparoscopy in diagnosis, staging, and treatment. Surg Oncol Clin N Am 21:515–31, 2012CrossRefPubMed Valle M, Federici O, Garofalo A: Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, and role of laparoscopy in diagnosis, staging, and treatment. Surg Oncol Clin N Am 21:515–31, 2012CrossRefPubMed
25.
Zurück zum Zitat Yan TD, Morris DL, Shigeki K, et al.: Preoperative investigations in the management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy: expert consensus statement. J Surg Oncol 98:224–7, 2008CrossRefPubMed Yan TD, Morris DL, Shigeki K, et al.: Preoperative investigations in the management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy: expert consensus statement. J Surg Oncol 98:224–7, 2008CrossRefPubMed
26.
Zurück zum Zitat Davies J, Chalmers AG, Sue-Ling HM, et al.: Spiral computed tomography and operative staging of gastric carcinoma: a comparison with histopathological staging. Gut 41:314–9, 1997PubMedCentralCrossRefPubMed Davies J, Chalmers AG, Sue-Ling HM, et al.: Spiral computed tomography and operative staging of gastric carcinoma: a comparison with histopathological staging. Gut 41:314–9, 1997PubMedCentralCrossRefPubMed
27.
Zurück zum Zitat de Bree E, Koops W, Kroger R, et al.: Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol 86:64–73, 2004CrossRefPubMed de Bree E, Koops W, Kroger R, et al.: Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol 86:64–73, 2004CrossRefPubMed
28.
Zurück zum Zitat Jacquet P, Jelinek JS, Steves MA, et al.: Evaluation of computed tomography in patients with peritoneal carcinomatosis. Cancer 72:1631–6, 1993CrossRefPubMed Jacquet P, Jelinek JS, Steves MA, et al.: Evaluation of computed tomography in patients with peritoneal carcinomatosis. Cancer 72:1631–6, 1993CrossRefPubMed
29.
Zurück zum Zitat Tempany CM, Zou KH, Silverman SG, et al.: Staging of advanced ovarian cancer: comparison of imaging modalities—report from the Radiological Diagnostic Oncology Group. Radiology 215:761–7, 2000CrossRefPubMed Tempany CM, Zou KH, Silverman SG, et al.: Staging of advanced ovarian cancer: comparison of imaging modalities—report from the Radiological Diagnostic Oncology Group. Radiology 215:761–7, 2000CrossRefPubMed
30.
Zurück zum Zitat de Bree E, Koops W, Kroger R, et al.: Preoperative computed tomography and selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 32:65–71, 2006CrossRefPubMed de Bree E, Koops W, Kroger R, et al.: Preoperative computed tomography and selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 32:65–71, 2006CrossRefPubMed
31.
Zurück zum Zitat Jacquet P, Jelinek JS, Chang D, et al.: Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery. J Am Coll Surg 181:530–8, 1995PubMed Jacquet P, Jelinek JS, Chang D, et al.: Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery. J Am Coll Surg 181:530–8, 1995PubMed
32.
Zurück zum Zitat Chua TC, Al-Zahrani A, Saxena A, et al.: Determining the association between preoperative computed tomography findings and postoperative outcomes after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 18:1582–9, 2011CrossRefPubMed Chua TC, Al-Zahrani A, Saxena A, et al.: Determining the association between preoperative computed tomography findings and postoperative outcomes after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 18:1582–9, 2011CrossRefPubMed
33.
Zurück zum Zitat Sugarbaker PH: Surgical responsibilities in the management of peritoneal carcinomatosis. J Surg Oncol 101:713–24, 2010CrossRefPubMed Sugarbaker PH: Surgical responsibilities in the management of peritoneal carcinomatosis. J Surg Oncol 101:713–24, 2010CrossRefPubMed
Metadaten
Titel
Correlation of Radiologic with Surgical Peritoneal Cancer Index Scores in Patients with Pseudomyxoma Peritonei and Peritoneal Carcinomatosis: How Well Can We Predict Resectability?
verfasst von
Kristina Flicek
Awais Ashfaq
C. Dan Johnson
Christine Menias
Sanjay Bagaria
Nabil Wasif
Publikationsdatum
01.02.2016
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 2/2016
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-015-2880-6

Weitere Artikel der Ausgabe 2/2016

Journal of Gastrointestinal Surgery 2/2016 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.